Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with...

Related Keywords

Toronto ,Ontario ,Canada ,China ,United States ,Chinese , ,Zai Lab Limited Nasdaq ,Zai Lab ,Exchange Commission ,Zai Lab Forward ,Zai Lab Limited ,Tumor Treating Fields ,Greater China ,Brain Metastases ,Chinese Journal ,Treating Fields ,Private Securities Litigation Reform Act ,